
    
      Dosages per drug are the same in either arm of the study: IV melarsoprol 1.8 mg/kg/day, daily
      for 10 days; IV eflornithine 400 mg/kg/day, 6-hourly for 7 days; oral nifurtimox 15 or 20
      (children <15 years) mg/kg/day, 8-hourly for 10 days.

      For efficacy assessment, patients are followed-up for 24 months after treatment, with planned
      clinical and laboratory controls.

      The safety assessment includes clinical and hematological adverse events.
    
  